NOTA-cRY9M

BALB/c nude (male, 4-5 weeks old, 18-21 g)^[1]

3.7 MBq

i.v.; single dose

Achieved peak tumor uptake of 3.69 %ID/g at 10 minutes postinjection, with uptake declining gradually to 3.33 %ID/g by 60 minutes.
Reached a maximum tumor-to-muscle ratio of 5.56 at 60 minutes, with tumor-to-liver and tumor-to-lung ratios reaching approximately 2.3 and 3.3, respectively, at 60 minutes.
Exhibited primarily renal excretion with low hepatic retention.\nAchieved peak tumor uptake of 3.11 %ID/g at 10 minutes postinjection.
Reached a maximum tumor-to-muscle ratio of 4.10 at 60 minutes.
Showed tumor uptake of 2.61 %ID/g in ex vivo biodistribution at 60 minutes.\nAchieved a maximum tumor uptake of 1.20 %ID/g, with a consistently low tumor-to-muscle ratio of 1.42 throughout the 60-minute imaging window.
Showed tumor uptake of 0.91 %ID/g in ex vivo biodistribution at 60 minutes.\nShowed a substantial reduction in [⁶⁸Ga]Ga-NOTA-cRY9M uptake (1.10 %ID/g) in FGFR1-knockdown Calu-3 xenografts compared to control Calu-3 tumors (3.83 %ID/g), with a corresponding tumor-to-muscle ratio of 2.11 vs. 5.89 in controls.